MetaCap

CAMP4 Therapeutics (CAMP) vs Prelude Therapeutics (PRLD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Prelude Therapeutics (PRLD) has outperformed CAMP4 Therapeutics (CAMP) over the past year, gaining 93.4% versus a gain of 30.7%. Prelude Therapeutics is the larger company by market cap ($258.6 million vs $237.8 million), about 1.1 times the size, while CAMP4 Therapeutics is growing revenue faster (+436.5% vs +73.4%). Prelude Therapeutics converts more of its revenue into profit, with a net margin of -819.6% versus -2298.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CAMP+30.69%PRLD+93.41%
+313%+139%-35%
Nov 21, 20251 yearNov 20, 2026
CAMP-64.65%PRLD+65.22%
+255%+76%-103%
Oct 7, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CAMP versus PRLD key metrics
MetricCAMPPRLD
Share price$3.79$3.23
Market cap$237.84M$258.63M
1-day change-5.25%-0.77%
YTD return-38.17%+11.38%
1-year return+30.69%+93.41%
5-year return—-76.93%
EPS (TTM)$-2.11$-0.59
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$3.50M$12.14M
Revenue growth (YoY)+436.50%+73.43%
Net income (latest FY)$-80.40M$-99.50M
Operating margin-1502.43%-861.33%
Net margin-2298.54%-819.59%
52-week high$7.75$6.83
52-week low$2.90$1.30
Distance from 52-week high-51.10%-52.71%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+169.66%+172.45%
Average volume238.88K432.74K
Shares outstanding62.75M65.34M
Employees4879
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PRLD has outperformed CAMP by 62.7 percentage points over the past year.
  • Prelude Therapeutics is more profitable, keeping -819.6 cents of every revenue dollar as net income versus -2298.5 cents for CAMP4 Therapeutics.
  • CAMP4 Therapeutics grew revenue faster in its latest fiscal year (+436.50% vs +73.43%).

About CAMP4 Therapeutics

CAMP stock →

Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders.

Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees

About Prelude Therapeutics

PRLD stock →

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET.

Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees

CAMP vs PRLD FAQ

Which is bigger, CAMP4 Therapeutics or Prelude Therapeutics?

Prelude Therapeutics (PRLD) is larger, with a market capitalization of $258.63M compared with $237.84M for CAMP4 Therapeutics (CAMP).

Which stock has performed better over the past year, CAMP or PRLD?

PRLD returned +93.41% over the past 12 months, compared with +30.69% for CAMP (price return, excluding dividends). Past performance does not predict future results.

Are CAMP4 Therapeutics and Prelude Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons